3.5200
-0.0200
(-0.56%)
At close: April 17 at 8:03:52 AM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | 7.02M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 21.07M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | 0.00% | 0.00% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| PL3.F | -- | -- | -- | -- |
| S&P 500 | 6.92% | 4.87% | 8.58% | 14.16% |
Related Tickers
0M4.DU Mersana Therapeutics Inc
0.3157
+12.99%
BT3.BE Lineage Cell Therapeutics Inc
0.3600
-1.10%
ICY.HA Incyte Corp
51.16
-0.31%
HTD.MU Corcept Therapeutics Inc
57.90
-3.60%
MVR0.BE Medivir AB
0.1372
-2.42%
DBV.F DBV Technologies S.A.
1.2520
+1.79%
05Y.MU Vivoryon Therapeutics NV
1.7140
0.00%
RASP Actavia Life Sciences, Inc.
0.0040
0.00%
MVR0.F Medivir AB (publ)
0.1458
-1.88%
96X.F FluoGuide A/S
3.1700
0.00%